BRPI0509529B1 - Forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diaza-biciclo[4.3.0]nonan-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinoli-nocarboxílico, seu uso, e medicamento - Google Patents
Forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diaza-biciclo[4.3.0]nonan-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinoli-nocarboxílico, seu uso, e medicamento Download PDFInfo
- Publication number
- BRPI0509529B1 BRPI0509529B1 BRPI0509529-8A BRPI0509529A BRPI0509529B1 BR PI0509529 B1 BRPI0509529 B1 BR PI0509529B1 BR PI0509529 A BRPI0509529 A BR PI0509529A BR PI0509529 B1 BRPI0509529 B1 BR PI0509529B1
- Authority
- BR
- Brazil
- Prior art keywords
- pradofloxacin
- trihydrate
- dihydro
- oxo
- cyano
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract description 8
- 229960001248 pradofloxacin Drugs 0.000 claims abstract description 46
- -1 nonan-8-yl Chemical group 0.000 claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 5
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- LZLXHGFNOWILIY-APPDUMDISA-N pradofloxacin Chemical compound C12=C(C#N)C(N3C[C@H]4NCCC[C@H]4C3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 LZLXHGFNOWILIY-APPDUMDISA-N 0.000 description 16
- 238000012986 modification Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003880 polar aprotic solvent Substances 0.000 description 3
- 238000001226 reprecipitation Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Ensaio | Rendimento | Quantidade de água | Condições |
B.1 | 91% | 25 ml | 85oC |
B.2 | 93% | 50 ml | 85oC |
B.3 | 92% | 100 ml | 85oC |
Ensaio | Ácido | Quantidade (mmol) | Rendimento % | Observação |
C.1 | ácido sulfúrico | 6 | 93,5 | precipitação em ácidos |
C.2 | ácido acético | 6 | 92 | |
C.3 | ácido fórmico | 6 | 81,7 | |
C.4 | ácido sulfúrico | 3 | 94,2 | precipitação em ácidos |
C.5 | ácido acético | 6 | 89,8 | precipitado a 60oC e temperado por 2 horas |
Claims (4)
- REIVINDICAÇÕES1. Trihidrato de pradofloxacina, caracterizado pelo fato de que apresenta a fórmula (II) eum difratograma de raios X apresentando as seguintes reflexões:
- 2 θ (2 Teta)10,623014,138618,403220,942222,560422,842024,516525,842626,497226,875927,1231 sendo que o sistema cristalino é monoclínico, e sendo que o grupo espacial é P21.2. Trihidrato de pradofloxacina, de acordo com a reivindicação 1, caracterizado pelo fato de que apresenta as seguintes características:Medidas da célula elementar a = 12,4790(18) Â α = 90o b = 12,1275(18) Â β = 111,009(6)° c = 15,010(2) Â γ = 90oPetição 870190001963, de 08/01/2019, pág. 6/112/2Volume 2120,6(5) A3.
- 3. Medicamento, caracterizado pelo fato de que compreende trihidrato de pradofloxacina, como definido na reivindicação 1 ou 2.
- 4. Uso de trihidrato de pradofloxacina, como definido na reivindicação 1 ou 2, caracterizado pelo fato de que é para fabricação de medicamentos para tratamento de doenças bacterianas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004015981A DE102004015981A1 (de) | 2004-04-01 | 2004-04-01 | Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE102004015981.5 | 2004-04-01 | ||
PCT/EP2005/002953 WO2005097789A1 (de) | 2004-04-01 | 2005-03-19 | Neue kristalline form von 8-cyan-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0509529A BRPI0509529A (pt) | 2007-09-18 |
BRPI0509529B1 true BRPI0509529B1 (pt) | 2019-05-21 |
BRPI0509529B8 BRPI0509529B8 (pt) | 2021-05-25 |
Family
ID=34962324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509529A BRPI0509529B8 (pt) | 2004-04-01 | 2005-03-19 | forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diaza-biciclo[4.3.0]nonan-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinoli-nocarboxílico, seu uso, e medicamento |
Country Status (32)
Country | Link |
---|---|
US (1) | US7977484B2 (pt) |
EP (1) | EP1737859B1 (pt) |
JP (1) | JP5190259B2 (pt) |
KR (1) | KR101217678B1 (pt) |
CN (1) | CN100591681C (pt) |
AR (2) | AR048099A1 (pt) |
AT (1) | ATE450536T1 (pt) |
AU (1) | AU2005231918B2 (pt) |
BR (1) | BRPI0509529B8 (pt) |
CA (1) | CA2561635C (pt) |
CY (2) | CY1109762T1 (pt) |
DE (3) | DE102004015981A1 (pt) |
DK (1) | DK1737859T3 (pt) |
ES (1) | ES2335899T3 (pt) |
GT (1) | GT200500043A (pt) |
HK (1) | HK1104537A1 (pt) |
HR (1) | HRP20100097T1 (pt) |
IL (1) | IL178353A (pt) |
MY (1) | MY140998A (pt) |
NO (1) | NO337279B1 (pt) |
NZ (1) | NZ550226A (pt) |
PE (1) | PE20060170A1 (pt) |
PL (1) | PL1737859T3 (pt) |
PT (1) | PT1737859E (pt) |
RU (1) | RU2383543C2 (pt) |
SI (1) | SI1737859T1 (pt) |
SV (1) | SV2006002070A (pt) |
TW (1) | TWI350755B (pt) |
UA (1) | UA84329C2 (pt) |
UY (1) | UY28828A1 (pt) |
WO (1) | WO2005097789A1 (pt) |
ZA (1) | ZA200608072B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006010642A1 (de) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
DE102006010643A1 (de) | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
DE102007026550A1 (de) * | 2007-06-08 | 2008-12-11 | Bayer Healthcare Ag | Extrudate mit verbesserter Geschmacksmaskierung |
PE20191462A1 (es) | 2017-02-13 | 2019-10-16 | Bayer Animal Health Gmbh | Composicion liquida que contiene pradofloxacina |
CN115710267A (zh) * | 2022-11-30 | 2023-02-24 | 天津大学 | 一种普拉沙星水合物晶体及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ331468A (en) | 1996-02-23 | 2000-02-28 | Bayer Ag | Substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4,3.0]-nonan-8-yl)-6-fluoro-1, 4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives |
DE19854357A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19854356A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19854355A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19908449A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure |
DE19908448A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
-
2004
- 2004-04-01 DE DE102004015981A patent/DE102004015981A1/de not_active Withdrawn
-
2005
- 2005-03-10 GT GT200500043A patent/GT200500043A/es unknown
- 2005-03-15 AR ARP050101004A patent/AR048099A1/es not_active Application Discontinuation
- 2005-03-19 CA CA2561635A patent/CA2561635C/en active Active
- 2005-03-19 RU RU2006138362/04A patent/RU2383543C2/ru active
- 2005-03-19 JP JP2007505435A patent/JP5190259B2/ja active Active
- 2005-03-19 AU AU2005231918A patent/AU2005231918B2/en active Active
- 2005-03-19 DK DK05716236.4T patent/DK1737859T3/da active
- 2005-03-19 CN CN200580010668A patent/CN100591681C/zh active Active
- 2005-03-19 WO PCT/EP2005/002953 patent/WO2005097789A1/de active Application Filing
- 2005-03-19 ES ES05716236T patent/ES2335899T3/es active Active
- 2005-03-19 AT AT05716236T patent/ATE450536T1/de active
- 2005-03-19 NZ NZ550226A patent/NZ550226A/en unknown
- 2005-03-19 DE DE502005008620T patent/DE502005008620D1/de active Active
- 2005-03-19 BR BRPI0509529A patent/BRPI0509529B8/pt active IP Right Grant
- 2005-03-19 UA UAA200611491A patent/UA84329C2/ru unknown
- 2005-03-19 EP EP05716236A patent/EP1737859B1/de active Active
- 2005-03-19 PL PL05716236T patent/PL1737859T3/pl unknown
- 2005-03-19 US US11/547,420 patent/US7977484B2/en active Active
- 2005-03-19 SI SI200530913T patent/SI1737859T1/sl unknown
- 2005-03-19 PT PT05716236T patent/PT1737859E/pt unknown
- 2005-03-30 UY UY28828A patent/UY28828A1/es not_active Application Discontinuation
- 2005-03-30 MY MYPI20051428A patent/MY140998A/en unknown
- 2005-03-31 TW TW094110161A patent/TWI350755B/zh active
- 2005-03-31 PE PE2005000369A patent/PE20060170A1/es not_active Application Discontinuation
- 2005-04-01 SV SV2005002070A patent/SV2006002070A/es unknown
-
2006
- 2006-09-28 ZA ZA2006/08072A patent/ZA200608072B/en unknown
- 2006-09-28 IL IL178353A patent/IL178353A/en active IP Right Grant
- 2006-10-26 KR KR1020067022260A patent/KR101217678B1/ko active IP Right Grant
- 2006-10-31 NO NO20064988A patent/NO337279B1/no unknown
-
2007
- 2007-09-05 HK HK07109664.9A patent/HK1104537A1/xx unknown
-
2010
- 2010-01-29 CY CY20101100090T patent/CY1109762T1/el unknown
- 2010-02-24 HR HR20100097T patent/HRP20100097T1/hr unknown
-
2011
- 2011-10-11 CY CY2011018C patent/CY2011018I1/el unknown
- 2011-10-11 DE DE201112100055 patent/DE122011100055I1/de active Pending
-
2016
- 2016-06-28 AR ARP160101954A patent/AR105177A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509529B1 (pt) | Forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diaza-biciclo[4.3.0]nonan-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinoli-nocarboxílico, seu uso, e medicamento | |
ES2237186T3 (es) | Modificacion cristalina b del acido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diazabiciclo (4.3.0)-6fluoro-1,4-dihidro-4-oxo-3-quinolincarboxilico. | |
WO2016146020A1 (zh) | 尼达尼布二乙磺酸盐晶体及其制备方法和用途 | |
US3657327A (en) | Prostaglandin salts of tris(hydroxymethyl)aminomethane | |
ES2217843T3 (es) | Modificacion cristalina a de acido 8-ciano-1-ciclopropil-7-(1s,6d-2,8-diazabiciclo(4.3.0)nonan-8-il)-6-fluor-1,4-dihidro-4-oxo-3-quinolincarboxilico. | |
WO2016150337A1 (zh) | Ahu377的晶型及其制备方法与用途 | |
KR100756474B1 (ko) | 8-시아노-1-사이클로프로필-7-(1s,6s-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 d | |
TWI234565B (en) | Semi-hydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | |
CZ299700B6 (cs) | Krystalová modifikace C kyseliny 8-kyano-1-cyklopropyl-7-(1S, 6S-2,8-diazabicyklo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolinkarboxylové, zpusob její výroby a její použití | |
Butler et al. | Cinchona alkaloids in pneumonia. I. miscellaneous alkaloids and some hydrocupreine ethers | |
CA3121405C (en) | Crystalline salts of corydalmine | |
WO2022225384A1 (es) | Proceso de obtención de rifapentina. con una nueva forma cristalina | |
ES2232311B1 (es) | Forma cristalina de gatifloxacino. | |
CN111057076A (zh) | 一种头孢吡肟杂质的制备方法及用途 | |
CN105315260A (zh) | 一种托布司他一水合物晶型及其制备方法 | |
CZ2016667A3 (cs) | Krystalické formy solithromycinu, jejich příprava a použití | |
ES2232310A1 (es) | Formula cristalina no higroscopica de gatifloxacino. | |
KR20180050451A (ko) | L-α-글리세릴 포스포릴 콜린 결정의 제조방법 | |
CS254211B1 (en) | Method of 7-(/2-thienyl/acetamido)cephaelosporanic acid's crystalline sterile sodium salt preparation | |
PT86774B (pt) | Processo para a preparacao de fosfatos de dobutamina monobasico | |
KR20140099435A (ko) | 목시플록사신 수성 제형 및 이의 제조방법 | |
KR20150080478A (ko) | 목시플록사신 수성 제형 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: BAYER ANIMAL HEALTH GMBH (DE) Free format text: TRANSFERIDO DE: BAYER HEALTHCARE AG |
|
B25A | Requested transfer of rights approved |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B22E | Other requirements [chapter 22.5 patent gazette] |
Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA. |
|
B16B | Notification of grant cancelled [chapter 16.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: RETIFICACAO REF. RPI 2524, DE 21/05/2019. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS. |
|
B25G | Requested change of headquarter approved |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE) |
|
B25A | Requested transfer of rights approved |
Owner name: BAYER ANIMAL HEALTH GMBH (DE) |
|
B25D | Requested change of name of applicant approved |
Owner name: ELANCO ANIMAL HEALTH GMBH (DE) |